Find your next paid study

University of California, San FranciscoNCT03933670

~$10 – $5,625

Phase I Trial of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma

Palliative systemic therapy is the standard treatment option for patients with pancreatic ductal adenocarcinoma (PDAC) and peritoneal metastasis (PM), who have…

Adenocarcinoma Pancreas

Northwell HealthNCT07253662

Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researc…

Astellas Pharma IncNCT07094204

~$10 – $8,750

Observational

A Pilot Study of an Individually Tailored, Supervised, Remotely Delivered Exercise Intervention to Improve Physical Function in Survivors of Gastroesophageal Cancer (PRECISE Study)

This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal canc…

Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8Clinical Stage I Gastric Cancer AJCC v8+9 more

Adenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma+2 more

Phase 2

A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma

The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX)…

Memorial Sloan Kettering Cancer CenterNCT05672524

Phase 3

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\]…

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8+2 more

SWOG Cancer Research NetworkNCT06998940

Advanced Solid MalignanciesNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)+1 more

A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants …

Bristol-Myers SquibbNCT07223047

The Canopy Cancer Collective Clinical Registry Protocol

The Canopy Cancer Collective Clinical Registry Protocol Non-Interventional Data and Sample Collection Registry Protocol Number of study sites 15 Study Design …

Gastrointestinal NeoplasmsPancreatic CancerColorectal Cancer+4 more

Canopy Cancer Collective, LLCNCT07605702

~$10 – $1,050

Observational

Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples for the Non-endoscopic Detection of Barrett's Esophagus With and Without Dysplasia

This clinical trial evaluates the use of cytosponge, a minimally invasive collection device, for the detection of Barrett's esophagus (BE) in patients undergoi…

Barrett EsophagusBarretts Esophagus With DysplasiaBarrett's Esophagus Without Dysplasia+1 more

Mayo ClinicNCT06071845

PDACPDAC - Pancreatic Ductal AdenocarcinomaNSCLC+5 more

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of or…

Tango Therapeutics, Inc.NCT06922591

~$10 – $8,750

Rectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage IIA Rectal Cancer AJCC v8+6 more

Organ Preservation With Active Surveillance After Chemoradiation in Rectal Cancer (OPTION)

This pilot trial studies how well active surveillance and chemotherapy before surgery work in treating participants with stage II-III rectal cancer. Active sur…

M.D. Anderson Cancer CenterNCT03594630

Advanced Solid TumorsNSCLC AdenocarcinomaCholangiocarcinoma+2 more

A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum admini…